Cancer Clinical Trial -Laekna -USOR 20208

An open-label randomize active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer.

Drug

Afuresertib, Paclitaxel

Phase

Phase II

Condition

Ovarian Clear Cell, Primary Peritoneal, Fallopian Tube

Keywords

Platinum-resistant High-grade serous